Status: Recruiting
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
Participants needed: 100
Trial details
Phase: Phase 2Age: 14+Biological sex: AllType: InterventionalSponsor: José Claudio Casali da RochaUpdated: Sep 11, 2025Locations: 1
Eligibility criteria
Age ≥ 14 years. [+6]
Age < 14 years. [+12]